Hence, BCR-ABL is the molecular target for CML treatment, which protects leukemic cells from the normal programmed cell death that leads to the development of CML (Cortes et al., 2021; Minciacchi et al., 2021). This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.